Research programme: kinase inhibitors - ICOS

Drug Profile

Research programme: kinase inhibitors - ICOS

Alternative Names: IC 87102; IC 87361; IC-491791; IC-491835

Latest Information Update: 20 Nov 2008

Price : $50

At a glance

  • Originator ICOS Corporation
  • Class Pyrimidinones; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Inflammation

Most Recent Events

  • 20 Nov 2008 Preclinical development is ongoing in USA
  • 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly
  • 19 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top